Payment overview · 2025
General Payments
$152.77
9 reported records · 7 companies
Healthcare provider profile · identity verified
Jean Lenz, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · OWATONNA, MN · NPI 1588044051
Verified facts
What the public records show
CMS Open Payments records show Jean Lenz, M.D. received $152.77 in general payments during 2025 across 9 reported records.
E.R. Squibb & Sons, L.L.C. accounted for 25.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $38.97 | 25.5% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $27.32 | 17.9% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $20.74 | 13.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $19.60 | 12.8% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $18.69 | 12.2% | 1 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $14.16 | 9.3% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.29 | 8.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $152.77 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $37.80 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $27.32 | 2 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $20.77 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $20.74 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $20.74 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $19.60 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $19.60 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $18.69 | 1 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $14.16 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $14.16 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $13.29 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 69 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 42 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
32 | 14 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
42 | 14 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
69 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
69 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 227 | 73 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 205 | 73 |
| Levothyroxine Sodium | Levothyroxine Sodium | 185 | 59 |
| Losartan Potassium | Losartan Potassium | 168 | 54 |
| Atorvastatin Calcium | Atorvastatin Calcium | 156 | 59 |
| Metoprolol Succinate | Metoprolol Succinate | 133 | 44 |
| Gabapentin | Gabapentin | 124 | 37 |
| Lisinopril | Lisinopril | 110 | 34 |
| Omeprazole | Omeprazole | 102 | 39 |
| Metformin Hcl | Metformin Hcl | 95 | 32 |
| Furosemide | Furosemide | 82 | 30 |
| Sertraline Hcl | Sertraline Hcl | 82 | 25 |
| Pantoprazole Sodium | Pantoprazole Sodium | 71 | 23 |
| Tamsulosin Hcl | Tamsulosin Hcl | 70 | 24 |
| Eliquis | Apixaban | 69 | 19 |
| Torsemide | Torsemide | 64 | suppressed |
| Potassium Chloride | Potassium Chloride | 62 | 14 |
| Simvastatin | Simvastatin | 58 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 57 | 22 |
| Montelukast Sodium | Montelukast Sodium | 52 | 21 |
| Trazodone Hcl | Trazodone Hcl | 51 | 16 |
| Metformin Hcl Er | Metformin Hcl | 50 | 22 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 50 | 12 |
| Tramadol Hcl | Tramadol Hcl | 50 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 46 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 46 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 45 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 44 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 44 | 18 |
| Jardiance | Empagliflozin | 42 | 14 |
| Lorazepam | Lorazepam | 42 | 18 |
| Allopurinol | Allopurinol | 41 | 15 |
| Carvedilol | Carvedilol | 39 | 15 |
| Ezetimibe | Ezetimibe | 39 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 37 | 16 |
| Spironolactone | Spironolactone | 37 | 15 |
| Ozempic | Semaglutide | 36 | suppressed |
| Synthroid | Levothyroxine Sodium | 32 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 30 | 11 |
| Xarelto | Rivaroxaban | 30 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 28 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 27 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 26 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 25 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 23 | suppressed |
| Meloxicam | Meloxicam | 23 | 11 |
| Mounjaro | Tirzepatide | 23 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 23 | suppressed |
| Finasteride | Finasteride | 22 | suppressed |
| Prednisone | Prednisone | 21 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Mirtazapine | Mirtazapine | 20 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 20 | suppressed |
| Alprazolam | Alprazolam | 19 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 18 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Clonazepam | Clonazepam | 16 | suppressed |
| Digoxin | Digoxin | 16 | suppressed |
| Famotidine | Famotidine | 16 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 16 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Klor-Con M20 | Potassium Chloride | 16 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 16 | suppressed |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Pregabalin | Pregabalin | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 11 |
| Celecoxib | Celecoxib | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 15 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Repatha Sureclick | Evolocumab | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Trospium Chloride | Trospium Chloride | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Azithromycin | Azithromycin | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Nabumetone | Nabumetone | 11 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $152.77 · 9 records | E.R. Squibb & Sons, L.L.C. | CAMZYOS, ELIQUIS, JARDIANCE, LEQVIO, NURTEC ODT, OPSUMIT, PAXLOVID, QULIPTA, UBRELVY, UPTRAVI, VOQUEZNA | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error